Background. The CDC has reported that seasonal influenza in 2017-2018 has been one of the worst on record, with hospitalization rates among the highest recorded, especially among younger age groups (age 50-65, hospitalization rate of 63.1 per 100,000 people compared with 35.1 in last severe season, 2015-2016) . Understanding how antiviral use affects rates and severity of complications is important to inform treatment decisions. This study used real-world US claims data for 3 flu seasons (2014) (2015) (2016) to understand the frequency of flu complications and how intervention with antivirals may affect their occurrence.
Methods. This was a retrospective cohort study using US commercial claims data from the 2014-2016 flu seasons. Patients with a diagnosis code for flu were identified and required to have continuous coverage for at least 365 days before and 91 days after diagnosis. Patients who were prescribed antivirals within 48 hours of the first flu-related encounter during the flu season were identified and propensity score matched to a comparative cohort without antiviral use within 48 hours but comparable baseline health resource utilization (HRU) and comorbidities. All-cause and respiratory-related HRU and costs in the 30 and 91 days after flu diagnosis were analyzed and compared.
Results. A total of 989,530 cases of influenza were identified over 3 flu seasons, with 60.2 percent receiving antiviral therapy (Table 1 ). In the matched sample, greater HRU and costs was identified in the cohort that did not receive antiviral therapy, with 15% vs. 10.4% (P < 0.001) visiting the ER, and 2.8% vs. 0.9% (P < 0.001) being admitted for inpatient care within the first month (Table 2) . Similarly, greater HRU was also seen in respiratory-related HRU and costs in the cohorts that did not receive antiviral therapy. Findings were similar in unmatched cohorts.
Conclusion. In data for the last 3 available flu seasons, flu patients treated with antivirals had less complications, healthcare resource utilization and overall costs than those who did not receive antiviral treatment. Limitations with this kind of study restrict the conclusions that can be made from this analysis, however suggest that treating flu can improve outcomes and resource utilization beyond symptom resolution. Background. Influenza is a common cause of morbidity and mortality in children. This was a retrospective study of hospitalized children with influenza at KKH admitted from January 2013 to December 2014 to compare the type of complications by age and underlying medical conditions.
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Methods. Influenza patients were identified by a positive polymerase chain reaction (PCR) or immunoflourescence antigen from nasopharyngeal swabs. Patients were grouped into neurologic, respiratory, other and no complication. Multinomial regression was used to compare age and complications with underlying disease.
Results. There were a total of 1,272 patients with a median age of 37 months (IQR 13-76 months). Influenza A constituted 76.3% with serotype H3N2 (54.5%), H1N1 (18.2%), unknown (5.4%). Influenza B constituted 22.9% with serotypes: Yamagata (16.3%), Victoria (5.7%). Only 4 patients (0.3%) had sequelae or death. 28% of influenza admissions had complications. The most common being neurologic 44% (n = 156) followed by respiratory 31% (n = 110). The most common clinical complications were: febrile seizure 34.1%, bronchitis/bronchiolitis 9.9%, pneumonia 7.3%. There was a significant difference between complications by male gender (P = 0.001), community acquisition (P = 0.007), influenza type, other positive viruses, comorbidity, asthma/ lung disease, neurologic disease, history of seizures, ICU/High Dependency admissions (all P ≤ 0.001), developmental delay (P = 0.002), Kawasaki disease on aspirin (P = 0.026), gastro-esophageal reflux (P = 0.034) and prescription of oseltamivir (P = 0.003). Neurologic complications occurred especially in the 2-< 5 year age group (37.2%), respiratory complications in the 6-23 month age group (39.1%). Age ≥5 year was more likely to have neurologic complication if they had a history of seizures (OR 14.2, P < 0.001). Age ≥2 years was more likely to have respiratory complications if they had asthma/ lung disease (OR 3.5, P < 0.001).
Conclusion. Although influenza mortality was low, 28% of influenza admissions in children had significant complications. Children with underlying medical problems should routinely receive influenza vaccinations to avoid complicated influenza illness.
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